Demand Cures

99¢ of every dollar received goes to fund cancer research

Brain Cancer

Phase I/II Trial of the IGF-1R Inhibitor for Patients with Recurrent Malignant Astrocytoma

Robert Aiken, MD
Rush University Medical Center

Clinical Title: Phase I/II Trial of the IGF-1R Inhibitor. AXL1717 for Treatment of Patients with Recurrent Malignant Astrocytoma

Clinical Description:

More effective therapies for treatment of malignant brain cancers are needed.  The most common and lethal of these tumors are anaplastic astrocytoma and glioblastomas.  Malignancies with current standard of care therapy of chemo-and radiation therapy usually relapse after 6-12 months.  In this PI initiated clinical trial, AXL1717, a new drug developed by Axelar, will be used to down regulate IGF-1R to destroy cancer cells.  The very encouraging preliminary data and the fact that this seems to be the only drug aimed at regulating IGF-1R that is able to cross the blood-brain barrier, makes this a truly significant project to provide potentially new and less toxic therapies for patients with little options.

Status: Active Trial

Accepting Patients? Yes

NIH Clinical Trial Link: http://www.clinicaltrials.gov/ct2/show/NCT01721577?term=axl1717&rank=1

DONATE to support Brain Cancer Research »

« Back to Funded Clinical Trials
Demand Cures Today Cancer Research

More About Our
Research

CANCER FACTS:

One American dies every 57 seconds from cancer.



These are loved ones, not statistics.

Cancer Fact

Demanding it all!
Funding innovative cancer research for
Treatments. Cures. Life.